V. Rigau, S. Zouaoui, H. Mathieu-daudé, A. Darlix, A. Maran et al., French brain tumor database: 5-year histological results on 25 756 cases, Brain Pathol, vol.21, issue.6, pp.633-677, 2011.

A. Darlix, S. Zouaoui, V. Rigau, F. Bessaoud, D. Figarella-branger et al., Epidemiology for primary brain tumors: a nationwide population-based study, J Neurooncol, vol.131, issue.3, pp.525-571, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01798680

D. N. Louis, A. Perry, G. Reifenberger, A. Von-deimling, D. Figarella-branger et al., The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta Neuropathol, vol.131, issue.6, pp.803-823, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01479018

K. Ludwig and H. I. Kornblum, Molecular markers in glioma, J Neurooncol. sept, vol.134, issue.3, pp.505-517, 2017.

A. M. Molinaro, J. W. Taylor, J. K. Wiencke, and M. R. Wrensch, Genetic and molecular epidemiology of adult diffuse glioma, Nat Rev Neurol, vol.15, issue.7, pp.405-422, 2019.

M. D. Wood, A. M. Halfpenny, and S. R. Moore, Applications of molecular neuro-oncology -a review of diffuse glioma integrated diagnosis and emerging molecular entities, Diagn Pathol. 9 avr, vol.14, issue.1, p.29, 2019.

J. E. Eckel-passow, D. H. Lachance, A. M. Molinaro, K. M. Walsh, P. A. Decker et al., Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors, N Engl J Med. 25 juin, vol.372, issue.26, pp.2499-508, 2015.

B. Malzkorn and G. Reifenberger, Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors, Pathologe. juin, vol.40, issue.1, pp.9-17, 2019.

M. J. Van-den-bent, M. Smits, J. M. Kros, and S. M. Chang, Diffuse Infiltrating Oligodendroglioma and Astrocytoma, J Clin Oncol. 20 juill, vol.35, issue.21, pp.2394-401, 2017.

D. N. Louis, H. Ohgaki, O. D. Wiestler, W. K. Cavenee, and . Lyon, WHO classification of tumours of the central nervous system, vol.408, 2016.

M. Wijnenga, H. J. Dubbink, P. J. French, N. E. Synhaeve, W. Dinjens et al., Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification, Acta Neuropathol. déc, vol.134, issue.6, pp.957-966, 2017.

A. Aibaidula, A. Chan, Z. Shi, Y. Li, R. Zhang et al., Adult IDH wild-type lower-grade gliomas should be further stratified, Neuro-Oncology, vol.19, issue.10, pp.1327-1364, 2017.

A. Chan, Y. Yao, Z. Zhang, Z. Shi, L. Chen et al., Combination genetic signature stratifies lower-grade gliomas better than histological grade, Oncotarget. 28 août, vol.6, issue.25, pp.20885-901, 2015.

D. E. Reuss, A. Kratz, F. Sahm, D. Capper, D. Schrimpf et al., Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities, Acta Neuropathol. sept, vol.130, issue.3, pp.407-424, 2015.

D. Stichel, A. Ebrahimi, D. Reuss, D. Schrimpf, T. Ono et al., Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma, Acta Neuropathol. nov, vol.136, issue.5, pp.793-803, 2018.

M. J. Bent, M. Weller, P. Y. Wen, J. M. Kros, K. Aldape et al., A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics, Neuro-Oncology. mai, vol.19, issue.5, pp.614-638, 2017.

K. Aoki, H. Nakamura, H. Suzuki, K. Matsuo, K. Kataoka et al., Prognostic relevance of genetic alterations in diffuse lower-grade gliomas, Neuro-oncology, vol.10, issue.1, pp.66-77, 2018.

D. J. Brat, R. Verhaak, K. D. Aldape, W. Yung, and S. R. Salama, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas, N Engl J Med. 25 juin, vol.372, issue.26, pp.2481-98, 2015.

D. J. Brat, K. Aldape, H. Colman, E. C. Holland, D. N. Louis et al., cIMPACT-NOW update 3: recommended diagnostic criteria for « Diffuse astrocytic glioma, IDHwildtype, with molecular features of glioblastoma, WHO grade IV », Acta Neuropathol, vol.136, issue.5, pp.805-815, 2018.

C. Tesileanu, L. Dirven, M. Wijnenga, J. Koekkoek, A. Vincent et al., Survival of diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria, Neurooncology, 2019.

Y. Ruano, M. Mollejo, T. Ribalta, C. Fiaño, F. I. Camacho et al., Identification of novel candidate target genes in amplicons of Glioblastoma multiforme tumors detected by expression and CGH microarray profiling, Mol Cancer. 26 sept, vol.5, p.39, 2006.

Y. Ruano, M. Mollejo, A. R. De-lope, J. L. Hernández-moneo, P. Martínez et al., Microarray-based comparative genomic hybridization (array-CGH) as a useful tool for identifying genes involved in Glioblastoma (GB), Methods Mol Biol, vol.653, pp.35-45, 2010.

G. A. Yeaney and D. J. Brat, What Every Neuropathologist Needs to Know: Update on cIMPACT-NOW, J Neuropathol Exp Neurol. 1 avr, vol.78, issue.4, pp.294-300, 2019.

D. N. Louis, D. W. Ellison, D. J. Brat, K. Aldape, D. Capper et al., cIMPACT-NOW: a practical summary of diagnostic points from Round 1 updates, Brain Pathol, vol.29, issue.4, pp.469-72, 2019.

D. N. Louis, P. Wesseling, W. Paulus, C. Giannini, T. T. Batchelor et al., cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC), Acta Neuropathol, vol.135, issue.3, pp.481-485, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01735097

D. N. Louis, C. Giannini, D. Capper, W. Paulus, D. Figarella-branger et al., cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, p.3
URL : https://hal.archives-ouvertes.fr/hal-01771458

, K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant, Acta Neuropathol, vol.135, issue.4, pp.639-681, 2018.

D. W. Ellison, C. Hawkins, D. Jones, A. Onar-thomas, S. M. Pfister et al., cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation, Acta Neuropathol, vol.137, issue.4, pp.683-690, 2019.

D. J. Brat, K. Aldape, H. Colman, D. Figrarella-branger, G. N. Fuller et al., cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDHmutant astrocytomas, Acta Neuropathol. mars, vol.139, issue.3, pp.603-611, 2020.

D. N. Louis, P. Wesseling, K. Aldape, D. J. Brat, D. Capper et al., cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading, Brain Pathol, vol.19, issue.2020

A. L. Lin, M. Rosenblum, I. K. Mellinghoff, V. S. Tabar, S. Ogilvie et al., Prognostic and radiographic correlates of a prospectively collected molecularly profiled cohort of IDH1/2-wildtype astrocytomas, Brain Pathol, vol.26, issue.2020

I. Jov?evska, Genetic secrets of long-term glioblastoma survivors, Bosn J Basic Med Sci. 20 mai, vol.19, issue.2, pp.116-140, 2019.

R. Chen, M. Smith-cohn, A. L. Cohen, and H. Colman, Glioma Subclassifications and Their Clinical Significance, Neurotherapeutics, vol.14, issue.2, pp.284-97, 2017.

A. Picca, G. Berzero, and M. Sanson, Current therapeutic approaches to diffuse grade II and III gliomas, Ther Adv Neurol Disord, vol.11, p.1756285617752039, 2018.

M. Weller, M. Van-den-bent, J. C. Tonn, R. Stupp, M. Preusser et al., European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas, Lancet Oncol, vol.18, issue.6, pp.315-344, 2017.

M. Geurts and M. J. Van-den-bent, On high-risk, low-grade glioma: What distinguishes high from low? Cancer, vol.15, pp.174-180, 2019.

M. Weller, L. Rhun, E. Preusser, M. Tonn, J. Roth et al., How we treat glioblastoma, ESMO Open, vol.4, issue.2, p.520, 2019.

J. Choi, S. H. Kim, S. S. Ahn, H. J. Choi, H. I. Yoon et al., Extent of resection and molecular pathologic subtype are potent prognostic factors of adult WHO grade II glioma, Sci Rep. 7 févr, vol.10, issue.1, p.2086, 2020.

D. Delev, D. H. Heiland, P. Franco, P. Reinacher, I. Mader et al., Surgical management of lower-grade glioma in the spotlight of the 2016 WHO classification system, J Neurooncol. janv, vol.141, issue.1, pp.223-256, 2019.

V. Körber, J. Yang, P. Barah, Y. Wu, D. Stichel et al., Evolutionary Trajectories of IDHWT Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis, Cancer Cell, vol.15, issue.4, pp.692-704, 2019.

A. Reinhardt, D. Stichel, D. Schrimpf, F. Sahm, A. Korshunov et al., Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations, Acta Neuropathol, vol.136, issue.2, pp.273-91, 2018.

H. Yan, D. W. Parsons, J. G. Mclendon, R. Rasheed, B. A. Yuan et al., IDH1 and IDH2 Mutations in Gliomas, N Engl J Med, vol.360, issue.8, pp.765-73, 2009.

D. Capper, D. Jones, M. Sill, V. Hovestadt, D. Schrimpf et al., DNA methylation-based classification of central nervous system tumours, Nature, vol.22, issue.7697, pp.469-74, 2018.

H. Binder, E. Willscher, H. Loeffler-wirth, L. Hopp, D. Jones et al., DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development, Acta Neuropathol Commun, vol.25, issue.1, p.59, 2019.

M. Hasselblatt, M. Jaber, D. Reuss, O. Grauer, A. Bibo et al., Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis, Journal of Neuropathology & Experimental Neurology. 1 juin, vol.77, issue.6, pp.422-427, 2018.

, Classification OMS 2016 des gliomes infiltrants, vol.1

, 072) RÉSUMÉ Introduction : Les astrocytomes IDH non mutés présentant les caractéristiques moléculaires des glioblastomes (glioblastomes moléculaires, GM) sont un nouveau sous-groupe de gliomes décrit en 2018 par le cIMPACT NOW. Il s'agit d'astrocytomes IDHwt de grade II ou III (AII/III IDHwt) comportant une amplification d'EGFR et/ou un gain du chromosome 7 associé à une perte du chromosome 10 et/ou une mutation de TERT, leur conférant un pronostic similaire aux glioblastomes IDHwt. L'objectif de ce travail est d, Courbes de survie (Kaplan Meier) des glioblastomes IDHwt (n = 23) en fonction du traitement par STUPP, vol.2, p.0

, Une analyse statistique a été réalisée afin de comparer la survie des GM et celle des AII/III IDHwt sans critère moléculaire de glioblastome, Matériel et Méthodes : L'ensemble des AII/III IDHwt ayant eu une CGH array entre le 1 er janvier 2016 et le 31 aout 2019 au CHU de Lille ont été inclus

, Le principal facteur impliqué dans la survie des GM était le statut de méthylation du promoteur de MGMT (HR 0,948, GM et 13 AII/III IDHwt ont été inclus, vol.420, p.0

, Après appariement des GM avec des glioblastomes IDHwt, la survie médiane entre ces deux groupes était similaire (14,36 mois vs 13,44 mois, vol.269, p.0

, Conclusion : Notre étude confirme que la survie des GM est similaire à celle des glioblastomes IDHwt. Elle est également comparable à celle des autres AII/III IDHwt. D'autres marqueurs moléculaires semblent nécessaires à rechercher afin d